New immunotherapy tested for Tough-to-Treat sarcomas
NCT ID NCT06939855
Summary
This study is testing an investigational immunotherapy drug called QL1706 for people with advanced bone and soft tissue sarcomas that cannot be surgically removed. The main goal is to see if the drug can control tumor growth for at least 12 weeks and to monitor its safety. About 45 adults who have already tried standard chemotherapy will receive the drug by IV every three weeks until their cancer worsens or they can no longer tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE AND SOFT TISSUE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.